{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T17:27:35Z","timestamp":1794158855758,"version":"4.8.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Graft-versus-host disease (GVHD) is the most important complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). We performed a prospective randomized, multicenter, phase 3 trial to study whether posttransplant cyclophosphamide (PT-Cy) combined with a short course of cyclosporine A (CsA) would result in a reduction of severe GVHD and improvement of GVHD-free, relapse-free survival (GRFS) as compared with the combination of CsA and mycophenolic acid (MPA) after nonmyeloablative (NMA) matched related and unrelated peripheral blood alloHSCT. Between October 2013 and June 2018, 160 patients diagnosed with a high-risk hematological malignancy and having a matched related or at least 8 out of 8 HLA-matched unrelated donor were randomized and allocated in a 1:2 ratio to CsA\/MPA or PT-Cy\/CsA; a total of 151 patients were transplanted (52 vs 99 patients, respectively). The cumulative incidence of grade 2 to 4 acute GVHD at 6 months was 48% in recipients of CsA\/MPA vs 30% following PT-Cy\/CsA (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.29-0.82; P = .007). The 2-year cumulative incidence of extensive chronic GVHD was 48% vs 16% (HR, 0.36; 95% CI, 0.21-0.64; P &amp;lt; .001). The 1-year estimate of GRFS was 21% (11% to 32%) vs 45% (35% to 55%), P &amp;lt; .001. With a median follow-up of 56.4 months, relapse incidence, progression-free survival, and overall survival were not significantly different between the 2 treatment arms. PT-Cy combined with a short course of CsA after NMA matched alloHSCT significantly improves GRFS due to a significant reduction in severe acute and chronic GVHD.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005847","type":"journal-article","created":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T14:18:50Z","timestamp":1644502730000},"page":"3378-3385","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":141,"title":["Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial"],"prefix":"10.1182","volume":"6","author":[{"given":"Annoek E. C.","family":"Broers","sequence":"first","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis N.","family":"de Jong","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;"},{"name":"2Department of Internal Medicine, Gelderse Vallei Hospital, Ede, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Bakunina","sequence":"additional","affiliation":[{"name":"3HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5113-0249","authenticated-orcid":false,"given":"Mette D.","family":"Hazenberg","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Amsterdam UMC, location AMC, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinus","family":"van Marwijk Kooy","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Isala Klinieken, Zwolle, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco R.","family":"de Groot","sequence":"additional","affiliation":[{"name":"6Department of Hematology, UMC Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"van Gelder","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Maastricht UMC+, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3914-7806","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Kuball","sequence":"additional","affiliation":[{"name":"8Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronno","family":"van der Holt","sequence":"additional","affiliation":[{"name":"3HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Meijer","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Amsterdam UMC, location VU, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan J.","family":"Cornelissen,","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"issue":"6","key":"2022060715215558200_B1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation","volume":"28","author":"Martin","year":"2010","journal-title":"J Clin Oncol."},{"issue":"16","key":"2022060715215558200_B2","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022060715215558200_B3","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med."},{"issue":"9","key":"2022060715215558200_B4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1470-2045(09)70225-6","article-title":"Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial","volume":"10","author":"Finke","year":"2009","journal-title":"Lancet Oncol."},{"issue":"1","key":"2022060715215558200_B5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med."},{"issue":"2","key":"2022060715215558200_B6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol."},{"issue":"2","key":"2022060715215558200_B7","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol."},{"issue":"8","key":"2022060715215558200_B8","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood.V89.8.3048","article-title":"Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation","volume":"89","author":"Storb","year":"1997","journal-title":"Blood."},{"issue":"11","key":"2022060715215558200_B9","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood."},{"issue":"4","key":"2022060715215558200_B10","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","article-title":"Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases","volume":"101","author":"Niederwieser","year":"2003","journal-title":"Blood."},{"issue":"11","key":"2022060715215558200_B11","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/bmt.2012.45","article-title":"Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation","volume":"47","author":"Ruutu","year":"2012","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"2022060715215558200_B12","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"issue":"16","key":"2022060715215558200_B13","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood."},{"issue":"31","key":"2022060715215558200_B14","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1200\/JCO.2013.54.0625","article-title":"Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning","volume":"32","author":"Kanakry","year":"2014","journal-title":"J Clin Oncol."},{"issue":"11","key":"2022060715215558200_B15","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood-2015-10-672071","article-title":"Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation","volume":"127","author":"Mielcarek","year":"2016","journal-title":"Blood."},{"issue":"3","key":"2022060715215558200_B16","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol."},{"issue":"21","key":"2022060715215558200_B17","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/bloodadvances.2019000236","article-title":"Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation","volume":"3","author":"Kwon","year":"2019","journal-title":"Blood Adv."},{"issue":"8","key":"2022060715215558200_B18","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood."},{"issue":"4","key":"2022060715215558200_B19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation."},{"issue":"6","key":"2022060715215558200_B20","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"2022060715215558200_B21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","article-title":"Chronic graft-versus-host disease","volume":"9","author":"Lee","year":"2003","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2022060715215558200_B22","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bmt.1705434","article-title":"Quality of life associated with acute and chronic graft-versus-host disease","volume":"38","author":"Lee","year":"2006","journal-title":"Bone Marrow Transplant."},{"issue":"17","key":"2022060715215558200_B23","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood."},{"issue":"2","key":"2022060715215558200_B24","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/S2352-3026(18)30214-X","article-title":"Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study","volume":"6","author":"Bonifazi","year":"2019","journal-title":"Lancet Haematol."},{"issue":"5","key":"2022060715215558200_B25","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.bbmt.2020.01.022","article-title":"Systematic review of patient-reported outcome measures in graft-versus-host disease","volume":"26","author":"Kilgour","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2022060715215558200_B26","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.bbmt.2016.03.004","article-title":"Graft-versus-host disease prophylaxis in unrelated peripheral blood stem cell transplantation with post-transplantation cyclophosphamide, tacrolimus, and mycophenolate mofetil","volume":"22","author":"Moiseev","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"issue":"11","key":"2022060715215558200_B27","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood.2019000487","article-title":"Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation","volume":"134","author":"Battipaglia","year":"2019","journal-title":"Blood."},{"issue":"1","key":"2022060715215558200_B28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-020-00923-0","article-title":"Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10\/10 HLA-matched unrelated donors","volume":"13","author":"Brissot","year":"2020","journal-title":"J Hematol Oncol."},{"issue":"2","key":"2022060715215558200_B29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0171-2985(96)80033-7","article-title":"Cyclophosphamide-induced immunological tolerance: an overview","volume":"195","author":"Mayumi","year":"1996","journal-title":"Immunobiology."},{"issue":"6","key":"2022060715215558200_B30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical BMT","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol."},{"issue":"13","key":"2022060715215558200_B31","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1182\/blood-2013-10-525873","article-title":"Donor CD4+\u00a0Foxp3+\u00a0regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice","volume":"124","author":"Ganguly","year":"2014","journal-title":"Blood."},{"issue":"211","key":"2022060715215558200_B32","doi-asserted-by":"crossref","first-page":"211ra157","DOI":"10.1126\/scitranslmed.3006960","article-title":"Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide","volume":"5","author":"Kanakry","year":"2013","journal-title":"Sci Transl Med."},{"issue":"6","key":"2022060715215558200_B33","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1172\/JCI124218","article-title":"Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression","volume":"129","author":"Wachsmuth","year":"2019","journal-title":"J Clin Invest."},{"issue":"2","key":"2022060715215558200_B34","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbmt.2019.09.030","article-title":"Optimized timing of post-transplantation cyclophosphamide in MHC-haploidentical murine hematopoietic cell transplantation","volume":"26","author":"Wachsmuth","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"2022060715215558200_B35","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2022060715215558200_B36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"18","key":"2022060715215558200_B37","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/bloodadvances.2020002074","article-title":"Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation","volume":"4","author":"Kalin","year":"2020","journal-title":"Blood Adv."},{"issue":"2","key":"2022060715215558200_B38","doi-asserted-by":"crossref","first-page":"86.e1","DOI":"10.1016\/j.jtct.2021.11.013","article-title":"Graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide versus cyclosporine A and methotrexate in matched sibling donor transplantation","volume":"28","author":"Nagler","year":"2022","journal-title":"Transplant Cell Ther."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3378\/1900381\/advancesadv2021005847.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/11\/3378\/1900381\/advancesadv2021005847.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T11:22:55Z","timestamp":1654600975000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/11\/3378\/483954\/Posttransplant-cyclophosphamide-for-prevention-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,6,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005847","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]}}}